Tenpoint Therapeutics Appoints Melissa Epperly as Chief Financial Officer
Melissa Epperly, CFO of Tenpoint Therapeutics • Photo Credit: Tenpoint Therapeutics
Corporate Business News Sponsored by VS News Network
LONDON and SEATTLE, June 2, 2025 (BUSINESS WATCH GLOBAL) — Biotechnology company Tenpoint Therapeutics, Ltd. has appointed Melissa Epperly as Chief Financial Officer.
Epperly will be responsible for overseeing financial strategy, capital markets activities, and operational finance functions as Tenpoint prepares for the potential U.S. launch of BRIMOCHOL™ PF, its lead therapeutic candidate for presbyopia.
Epperly has over 20 years of experience in financial leadership roles within the biopharmaceutical sector. She most recently served as Chief Financial Officer at Zentalis Pharmaceuticals, where she led the company through its initial public offering and subsequent financing rounds, raising more than $1.25 billion. Her previous roles include CFO positions at PsiOxus Therapeutics and R-Pharm US, as well as strategic and financial positions at Anchorage Capital, Goldman Sachs, Bain & Company, and Morgan Stanley.
Epperly currently serves on the boards and audit committees of Roivant Sciences and Nautilus Biotechnology. She holds an MBA from Harvard Business School and a BA in Biochemistry and Economics from the University of Virginia.
"Melissa brings the vision, energy, and financial firepower we need as we prepare for the launch of BRIMOCHOL™ PF into global markets. Her deep capital markets experience and strong operational command will be a tremendous asset as Tenpoint grows into a commercial-stage company," said Henric Bjarke, Chief Executive Officer, Tenpoint Therapeutics.
"It’s an honor to join Tenpoint at such a defining moment. With breakthrough science, bold goals, and a clear vision for impact, this team is poised to do something extraordinary. I’m eager to help shape what’s ahead as we advance BRIMOCHOL™ PF and build toward lasting growth," said Melissa Epperly, Chief Financial Officer, Tenpoint Therapeutics.
For more information, visit www.tenpointtherapeutics.com.
Source: Tenpoint Therapeutics
